Lantheus Holdings appoints Julie McHugh as director
Ms. McHugh, who will serve as a member of the Compensation Committee of the Board, brings over 30 years of experience in the pharmaceutical, biotech and medical devices industries.
Ms. McHugh recently served as Chief Operating Officer of Endo Health Solutions, Inc., where she was responsible for the specialty pharmaceutical and generic drug businesses.
Prior to that, Ms. McHugh was CEO of Nora Therapeutics, Inc., a venture capital backed biotech start-up company focused on developing novel therapies for the treatment of infertility disorders.
Previously, she served as Company Group Chairman for Johnson & Johnson's worldwide virology business unit, and prior to that, she was President of Centocor, Inc., a J&J subsidiary.
Ms. McHugh currently serves on the Board of Directors of Aerie Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., New Xellia Group A/S and Trevena Pharmaceuticals, Inc.
Ms. McHugh previously served on the Board of Directors of the Biotechnology Industry Organization, the New England Healthcare Institute, the Pennsylvania Biotechnology Association, EPIRUS Pharmaceuticals, Inc. and ViroPharma Inc.
She received a Master of Business Administration from St. Joseph's University and a Bachelor of Science from Pennsylvania State University. ■
LATEST MOVES FROM Massachusetts
- PTC appoints Corinna Lathan to board
- J.Jill appoints James S. Scully to board
- Raytheon elects Robert O. Work as director
- Xenetic Biosciences appoints three directors
- Insulet appoints two to board
More inside POST
Wrong shade of gray cost Lego millions Companies